Treatment of Headaches After Shingles

First-Line Antiviral Treatment

The American College of Physicians recommends initiating oral antiviral therapy with acyclovir 800 mg five times daily, valacyclovir 1000 mg three times daily, or famciclovir 500 mg three times daily for 7-10 days to reduce viral replication and control persistent neurological symptoms including headache in patients with headaches following shingles 1, 2
Acyclovir 800 mg orally 5 times daily for 7-10 days is the standard treatment option for post-shingles headaches, as recommended by the Infectious Diseases Society of America 1
Valacyclovir 1000 mg orally 3 times daily for 7 days offers better bioavailability and less frequent dosing, which improves adherence, according to the American Academy of Neurology 1
Famciclovir 500 mg orally 3 times daily for 7 days is an alternative with comparable efficacy and convenient dosing, as suggested by the American College of Physicians 1

For severe or complicated cases, particularly in immunocompromised patients or when HSV meningitis is suspected, intravenous acyclovir 10 mg/kg every 8 hours is indicated, as recommended by the Infectious Diseases Society of America 3, 4, 2
Key indicators for IV therapy include headache accompanied by fever, photophobia, or meningismus, which are signs of possible HSV-2 meningitis, according to the American Academy of Neurology 3, 4
Immunocompromised status with disseminated disease is also an indicator for IV therapy, as suggested by the Centers for Disease Control and Prevention 1, 2
Severe neurological symptoms or altered mental status require IV therapy, as recommended by the Neurocritical Care Society 3, 4

Analgesics, including NSAIDs such as ibuprofen 400-800 mg every 6 hours or naproxen 275-550 mg every 2-6 hours, can be used for mild to moderate pain management in patients with post-herpetic headache, as suggested by the American Academy of Pain Medicine 5

It is essential to distinguish HSV meningitis from HSV encephalitis, as encephalitis requires 14-21 days of IV acyclovir due to high neurologic morbidity and mortality, as recommended by the Infectious Diseases Society of America 3, 4
Valacyclovir 500 mg twice daily is insufficient for central nervous system penetration and may cause rebound symptoms upon discontinuation, according to the American Academy of Neurology 3, 4
Topical antiviral therapy is substantially less effective than systemic therapy and should not be used, as suggested by the American College of Physicians 1, 2
Antiviral medications do not eradicate latent virus but help control symptoms and reduce complications, as recommended by the Centers for Disease Control and Prevention 1, 2

For immunocompromised patients with severe VZV infections, high-dose IV acyclovir is the treatment of choice, and immunosuppressive therapy should be temporarily discontinued, as recommended by the Infectious Diseases Society of America 1, 2
Elderly patients are at higher risk for complications, including postherpetic neuralgia, and should have antiviral therapy initiated even in the absence of rash when zoster sine herpete is suspected, according to the American Geriatrics Society 1

Patients should be monitored for complete resolution of headache and other neurological symptoms, as recommended by the American Academy of Neurology 1
Development of postherpetic neuralgia, which can persist for weeks to months after rash resolution, should be monitored, although the optimal monitoring strategy is not specified in the provided references
Any signs of disseminated infection or complications, especially in immunocompromised patients, should be monitored, as suggested by the Centers for Disease Control and Prevention 1, 2